Sold
Cagrilintide

Cagrilintide

90,00$

Description

Cagrilintide is a long-acting, synthetic amylin and calcitonin receptor agonist (DACRA) peptide currently under research for its effects on appetite regulation, weight management, and metabolic control. It is engineered to mimic the satiety-inducing and glycemic effects of native amylin but with enhanced resistance to enzymatic degradation and a prolonged half-life. Epigenetix Labs supplies Cagrilintide as a high-purity, research-grade peptide in sterile vials for laboratory studies only. Not approved for human or veterinary use.

10 research based reasons to study

  • Potent appetite suppression
  • Slows gastric emptying
  • Promotes weight loss in obesity models
  • Resistant to enzymatic degradation
  • Dual amylin/calcitonin receptor activity
  • Synergy with GLP-1 receptor agonists
  • Glycemic regulation in diabetes research
  • Once-weekly dosing profile
  • Low risk of amyloid aggregation
  • Supports multi-hormonal therapy research
SKU: GCL5 Categories:,
Additional information

Additional information

Weight 0,006 kg
Dimensions 1,5 × 1,5 × 3,5 cm
Research Applications

Obesity and weight management
• Glycemic control and diabetes
• Appetite and satiety research
• Pharmacokinetic and long-acting peptide design
• Combination therapies with incretin mimetics.
Key Research Findings

Once-weekly cagrilintide induces 6–11% weight loss in overweight and obese human subjects (Lancet, 2021)
• Combination with semaglutide results in approximately 20% weight loss in 32-week clinical trials
• Demonstrates enhanced metabolic control and body composition improvements in rodent studies
• Synergistic effects with incretin-based therapies.
Scientific background

Cagrilintide is a modified analog of human amylin with additional substitutions to increase its stability and dual-receptor agonist profile (amylin and calcitonin receptors).
It is part of the DACRA (dual amylin and calcitonin receptor agonist) class, which has demonstrated potent effects on appetite suppression, delayed gastric emptying, and improved glycemic control in preclinical and clinical studies. Cagrilintide is being investigated in combination with GLP-1 receptor agonists for enhanced weight loss outcomes.
Purity & Manufacturing Standards

Cagrilintide is synthesized via solid-phase peptide synthesis (SPPS), purified by HPLC, and validated by MS. Each batch is produced in ISO 9001:2015-certified facilities to ≥98% purity.
Legal Disclaimer

This peptide is for scientific laboratory research use only. Not for human or veterinary use. Not for food, supplements, cosmetics, or therapeutic applications. Not evaluated by the FDA or other authorities.
Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Cagrilintide”

Your email address will not be published. Required fields are marked *

12345

Related products

  • hCG
    Select options This product has multiple variants. The options may be chosen on the product page

    hCG

    <

    55,00$
  • MOTS-cSold
    Select options This product has multiple variants. The options may be chosen on the product page

    MOTS-c

    <

    Price range: 58,00$ through 90,00$
  • Ipamorelin
    Select options This product has multiple variants. The options may be chosen on the product page

    Ipamorelin

    <

    57,00$
  • AOD
    Select options This product has multiple variants. The options may be chosen on the product page

    AOD‑9604

    <

    75,00$